Search the Newsreel

Renaissance Technologies LLC Sells 5,700 Shares of Axsome Therapeutics, Inc. $AXSM

Renaissance Technologies LLC reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.4% in the first quarter, selling 5,700 shares and now owning 164,300 shares worth $27.77 million. Despite this, several other institutional investors increased their holdings, and analysts have a "Moderate Buy" rating with …

Somnigroup International (SGI) Reports Next Week: Wall Street Expects Earnings Growth

The market expects Somnigroup International (SGI) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

SummitTX Capital L.P. Makes New $2.59 Million Investment in Axsome Therapeutics, Inc. $AXSM

SummitTX Capital L.P. has made a new $2.59 million investment in Axsome Therapeutics, Inc. by purchasing 15,304 shares. This move is part of the broader institutional interest in Axsome Therapeutics, with other hedge funds also adjusting their positions. Despite a wider-than-expected quarterly loss, analysts …

Axsome Therapeutics Inc (AXSM) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Axsome Therapeutics Inc (AXSM), noting its current valuation score of 9.71, ranking 10th in the Pharmaceuticals industry. The P/E ratio is reported at -62.84, which is significantly below its recent high and slightly above its recent low. The …

Healthcare of Ontario Pension Plan Trust Fund Invests $16.49 Million in Axsome Therapeutics, Inc. $AXSM

The Healthcare of Ontario Pension Plan Trust Fund has invested $16.49 million in Axsome Therapeutics, acquiring 97,550 shares. This comes as institutional investors now own 81.49% of the company, despite recent insider sales totaling $37.23 million. Axsome Therapeutics reported significant revenue growth of 57.4% …

Somnigroup Announces Refinancing of Credit Facilities

Somnigroup International Inc. announced the successful refinancing of its $2.9 billion senior secured credit facilities, including a $1.7 billion revolver and a $1.2 billion term loan A. This amendment lowers the company's cost of capital, extends debt maturities, and enhances financial flexibility. The transaction …

BlackRock, Inc. (AXSM) reports 2.74M Axsome Therapeutics shares in Schedule 13G/A

BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, disclosing a beneficial ownership of 2,736,503 shares of Axsome Therapeutics, Inc. common stock, which represents a 5.3% stake. BlackRock maintains sole voting power over 2,649,256 shares and sole dispositive power over all …

Axsome Therapeutics, Inc. $AXSM Shares Sold by Orbimed Advisors LLC

Orbimed Advisors LLC reduced its stake in Axsome Therapeutics ($AXSM) by 15.5% in the first quarter, selling 39,200 shares and retaining 213,921 shares valued at $36.2 million. Despite the company reporting Q1 revenue of $191.2 million, which beat estimates, it posted an adjusted loss …

Axsome Therapeutics Inc (AXSM) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides information on Axsome Therapeutics Inc (AXSM) regarding its dividend history and stock splits. It indicates that the company has distributed a total of $0.00 in dividends over the past five years, with "No Data" available for specific dividend dates. The page …

Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM

Caxton Associates LLP has made a new investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by purchasing 4,311 shares worth approximately $729,000 during the first quarter. Institutional investors now own 81.49% of the company, and analysts have a "Moderate Buy" rating with an average price target …

SomnoMed Posts Record Half-Year Revenue and 35% EBITDA Lift, But FY26 Verdict Is Still to Come

SomnoMed Co-CEO Steps Down; Fiscal 2026 Revenue Misses Guidance

SomnoMed Director Amrita Singh Blickstead Exits Company After Shareholding Disposal

FDA Acceptance of AXS-12 NDA for Narcolepsy Might Change The Case For Investing In Axsome (AXSM)

Axsome Therapeutics recently received FDA acceptance for its AXS-12 New Drug Application for cataplexy in narcolepsy, with a target action date of May 1, 2027, and no advisory committee planned. This milestone is crucial for Axsome's CNS portfolio, adding a potential orphan indication and …

California Public Employees Retirement System Makes New Investment in Axsome Therapeutics, Inc. $AXSM

The California Public Employees Retirement System (CalPERS) has initiated a new investment in Axsome Therapeutics (NASDAQ:AXSM), acquiring 50,879 shares valued at approximately $8.6 million during the first quarter, representing 0.10% of the company. This comes even as insider selling was noted, with the COO …

Axsome Therapeutics (AXSM) Wins FDA NDA Acceptance, Is The Stock Fully Valued?

Axsome Therapeutics (AXSM) recently received FDA acceptance for its New Drug Application for AXS-12, an investigational treatment for cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. Despite a significant 139.02% return over the past year, leading to a current share price …

AXSM|Axsome Therapeutics Inc|Price:241.000|Chg%:-0.530

Axsome Therapeutics Inc (AXSM) is trading at $241.00 with a slight decrease of 0.22%. The company, which specializes in CNS conditions, has strong fundamentals and high growth potential, with an average revenue growth of 135.96% year-on-year over the past three years. Analysts have rated …

Axsome Therapeutics, Inc. (AXSM) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Axsome Therapeutics, Inc. (AXSM), including its current stock price, historical data, financial performance, and analyst ratings. It details the company's biotechnology focus, its commercial products for CNS disorders like Auvelity and Sunosi, and its pipeline of …

Sompo Holdings,Inc. Revenue Breakdown – TSE:8630

First Trust Advisors LP Increases Position in Axsome Therapeutics, Inc. $AXSM

First Trust Advisors LP significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 1,230.2% in the first quarter, now owning 577,479 shares valued at $97.6 million. Despite missing EPS estimates, Axsome's revenue grew 57.4% year-over-year. Analysts maintain a "Moderate Buy" rating with an average …

Axsome Therapeutics, Inc. Revenue Breakdown – NASDAQ:AXSM

This article provides a revenue breakdown for Axsome Therapeutics, Inc. (NASDAQ: AXSM). It highlights that the company generated $633.80 million USD last year, with its "Novel Therapies for the Management of Central Nervous System Disorders" segment contributing the most at $638.50 million USD. The …

Somerset Minerals Limited Revenue Breakdown – ASX:SMM

Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12, a treatment for cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting, which could indicate a …

Somnigroup Stock Outlook Hinges on Synergies and Demand Recovery

Somnigroup International Inc. (SGI) is navigating a period of integration and strategic growth following its Mattress Firm acquisition. The company's future performance relies heavily on realizing acquisition synergies, expanding its international footprint, and maintaining operational discipline, particularly against a backdrop of muted bedding demand …

Is SGI Stock a Buy Now or a Wait-and-See on Bedding Demand?

Somnigroup International Inc. (SGI) presents a mixed investment case, characterized by strong scale, synergy potential from the Mattress Firm acquisition, and international growth, offset by sluggish global bedding demand and lingering cost pressures. While the company demonstrates resilience in its financials and has a …

AXSOME THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $265 FROM $250

Leerink Partners has raised its target price for Axsome Therapeutics Inc. (AXSM) to $265 from $250. This change suggests an increased positive outlook from the financial institution regarding the company's future performance. The article is very brief and does not provide further details on …

Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets

BMO Capital Markets upgraded Axsome Therapeutics (NASDAQ:AXSM) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating and an average price target of $261.48 among analysts. Despite the company missing Q1 earnings estimates, its revenue increased by 57.4% year-over-year. The stock opened at …

Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research

Zacks Research has downgraded Axsome Therapeutics (NASDAQ:AXSM) from a "hold" to a "strong sell" rating. This comes despite a broader "Moderate Buy" consensus among analysts with a price target of $261.48. The company recently reported mixed quarterly results, with an EPS of -$1.26 missing …

AXSM Initiated Coverage by BMO Capital -- Outperform Rating Assi

BMO Capital has initiated coverage on Axsome Therapeutics (AXSM) with an Outperform rating and a price target of $310.00. While GuruFocus indicates the stock is 2.1% undervalued with a GF Value™ of $226.26, its GF Score™ of 52/100 points to average performance, burdened by …

Somnigroup (SGI) Stock May Be 27% Undervalued Following SEC Filing

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Somnigroup International has delivered a 92.5% total return over the past five years, yet the current valuation picture is mixed, with a Discounted Cash …

Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides

Axsome Therapeutics Inc. (AXSM) has released its Q3 2024 earnings report, showing a beat on both EPS and revenue expectations. The company reported actual EPS of -$1.34 against a consensus of -$1.38, and actual revenue of $104.76 million compared to an expected $98.37 million, …

Tempur Sealy Slumps on Joining with Ronald McDonald House.

Tempur Sealy Canada, in partnership with Mega Group, donated just over $29,000 to Ronald McDonald House across Canada through a year-long fundraising initiative. This donation was generated from the sale of Sealy mattresses, with a portion of the proceeds supporting families with critically ill …

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

BMO Capital has initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $310. This follows several recent positive developments for Axsome, including the FDA's acceptance of their New Drug Application for AXS-12 for narcolepsy treatment and the initiation of …

Winsome Yarns appoints Ms. Riya Pawar as Company Secretary and Compliance Officer

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts

Axsome Therapeutics (NASDAQ:AXSM) has received a "Moderate Buy" consensus rating from 21 analysts, with an average 12-month price target of $259.05. Despite reporting quarterly revenue of $191.2 million, exceeding expectations and up 57.4% year-over-year, the company posted a larger-than-expected loss of $1.26 per share, …